Background-Lipoprotein oxidation plays an important part in atherogenesis. Autoantibodies to oxidation-specific epitopes of LDL occur in plasma and atherosclerotic lesions of humans and animals. The potential role of these autoantibodies in atherogenesis still remains unsolved. We studied the relationship between different isotypes of autoantibodies to copper-oxidized LDL and malondialdehyde-modified LDL (MDA-LDL) and carotid artery intimamedia thickness (IMT) in a population-based cohort of 1022 middle-aged men and women. In addition, we studied the relation of C-reactive protein (CRP) to IMT. Methods and Results-The levels of IgM, IgG, and IgG2 autoantibodies binding to MDA-LDL and copper-oxidized LDL were determined in plasma samples by chemiluminescence-based ELISA. IMT and the number of plaques were measured ultrasonographically. The subjects were divided into tertiles for antibody titers. We found an inverse association between IMT and IgM autoantibody titers to MDA-LDL that remained statistically significant after adjusting for age, gender, LDL cholesterol, systolic blood pressure, CRP, and smoking. CRP was not independently associated with IMT.
H ypercholesterolemia is the major factor involved in the initiation of fatty streak formation, the initial lesion of the atherogenic process. However, there are numerous other factors that may influence the transformation of these fatty streaks into complex plaques. 1 It is now well recognized that this progressive atherogenic process has many characteristics of a chronic inflammatory process, and experimental evidence in animal models demonstrate that the immune system plays an important role and may alter the course of the atherosclerotic process. 2, 3 Lipoprotein oxidation is known to enhance atherogenesis by several different of mechanisms. 2, 3 During oxidation, a variety of highly reactive breakdown products, such as malondialdehyde (MDA), 4 are generated, which additionally modify closely associated lipids and proteins into immunogenic epitopes. Autoantibodies to oxidation-specific epitopes of LDL, such as MDA-modified LDL (MDA-LDL), occur in plasma and atherosclerotic lesions of humans and animals. [5] [6] [7] The potential role of these autoantibodies in the atherogenic process is complex and still remains unsolved. Indeed, some studies demonstrate that immunization of animals with oxi-dized LDL (OxLDL) induces high levels of antibodies to OxLDL and decreases atherosclerosis, 8 -11 whereas other studies demonstrate elevated antibody titers to OxLDL in humans and animals with increased atherosclerosis. [12] [13] [14] The relationship between carotid artery intima-media thickness (IMT) and cardiovascular diseases has been well documented. 15 The aim of the present study was to investigate the relationship between different isotypes of autoantibodies to OxLDL and carotid artery IMT in a large, randomly selected population-based cohort of middle-aged men and women (nϭ1022). In addition, we measured CRP and investigated its relationship to IMT.
Methods

Sample
The Oulu Project Elucidating Risk of Atherosclerosis (OPERA) project is a population-based, epidemiological study addressing the risk factors and end points of atherosclerotic cardiovascular diseases. The detailed study design has been previously described. 16 The participants were randomly selected from Finnish national population registers. In this study, a total of 1022 participants (508 men and 514 women) were screened. Eighty-three subjects had coronary heart disease, and 58 subjects were diabetic. Five hundred twenty-nine subjects used blood pressure-lowering medication, 29 subjects used lipid-lowering medication, 55 subjects used aspirin, 17 subjects used oral diabetes medication, 12 subjects used insulin, and 109 subjects were undergoing hormone replacement therapy. The characteristics of the participants are shown in Table 1 . The study was approved by the Ethical Committee of the Faculty of Medicine, University of Oulu, and followed the Declaration of Helsinki.
Clinical Measurements
Plasma cholesterol levels were determined by enzymatic colorimetric methods, and lipoprotein fractions were separated by ultracentrifugation. The glucose concentrations were measured using the glucose-oxidase method (Diagnostica, Merck). C-reactive protein was measured using commercially available ELISA kits (Diagnostic Systems Laboratories).
Autoantibody Measurements to OxLDL
The levels of IgM and IgG and IgG2 autoantibodies binding to MDA-LDL and copper-oxidized (CuOx)-LDL were determined by chemiluminescence-based ELISA. 17 MDA-LDL and CuOx-LDL were generated as previously described, 10, 18 and the degree of the modification was verified by TNBS method 19 and testing monoclonal anti-OxLDL antibody binding (EO6 binding 17 ). The same modified LDL preparation was used throughout the study. Antigens at 10 g/mL in PBS-EDTA (PBS with 0.27 mmol/L EDTA) were incubated overnight at 4°C in white MicroFluor plates (Dynatech Laboratories). Plates were washed 3 times with PBS-EDTA with an automated plate washer and blocked with PBS-EDTA containing 1% BSA for 30 minutes. Plasma samples were diluted 1:1000 for IgM, 1:500 for total IgG, and 1:50 for IgG2 and incubated 1 hour at room temperature. Plates for IgM and IgG were incubated with an alkaline phosphatase-labeled goat anti-human IgM or IgG (Sigma) for 1 hour at room temperature. Finally, 25 L of a 50% solution of Lumi-Phos530 (Lumigen) was added and the luminescence was determined after 90 minutes with Victor 2 Luminometer (Wallac, Perkin-Elmer). Plates for IgG2 were first incubated with biotin-labeled mouse anti-human IgG2 (Pharmingen), followed by alkaline phosphatase-labeled NeutrAvidin (Pierce) and LumiPhos. Triplicate determinations were performed for each plasma sample. A standard curve of human IgM or IgG and a control plasma sample was added to each plate to correct potential variations between the assays. The interassay coefficients of variation were as follows: IgM, 13.6% for CuOx-LDL and 10.0% for MDA-LDL; IgG, 11.5% for CuOx-LDL and 9.14% for MDA-LDL; and IgG2, 11.9% for CuOx-LDL and 10.3% for MDA-LDL.
Carotid Ultrasonography
The intima-media thickness and the number of the atheromatous plaques were measured by a trained radiologist without knowledge of clinical data. A duplex ultrasound system with 7.5-MHz scanning frequency in B-mode, pulsed Doppler mode, and color mode was used (Toshiba SSA-270A; Toshiba Corp). IMT, defined as the distance between the media-adventitia interface and the lumenintima interface, was measured on the following 5 points at each side: internal carotid artery, bifurcation, and common carotid artery (at 3 different locations). The mean IMT was defined as the mean of internal carotid artery, bifurcation, and the 3 highest common carotid artery measurements. An arterial plaque was defined as an echogenic structure having an IMT more than 50% greater than those of the neighboring sites. 20 The reproducibility was assessed from the videotapes of 31 randomly selected study subjects by 2 radiologists blind to the original results. The intrareader variability and correlation coefficient (Pearson) were 3% and 0.97 for the mean IMT. The respective interreader variability and correlation values were 7.2% and 0.93.
Statistical Analyses
The subjects were divided into tertiles of antibodies. ANOVA was used to compare IMT and Kruskal-Wallis test was used to compare the number of plaques between the tertiles. The results were adjusted for age, gender, systolic blood pressure, LDL cholesterol, CRP, and pack-years using ANCOVA. Logarithmic transformation was used for pack-years (skewed distribution). ANOVA and ANCOVA were used to investigate the relationship between CRP and IMT. Statistical significance was defined as PϽ0.05. SPSS 10.1 (SPSS Inc) was used in all analyses.
Results
We first analyzed the different antibody isotype titers to OxLDL, and our data showed statistically significant differences in the IMT in the following subclasses of autoantibodies: IgM autoantibody titers to MDA-LDL and CuOx-LDL and also IgG autoantibody titers to CuOx-LDL. No trends were seen in IgG titers to MDA-LDL or IgG2 titers either to MDA-LDL or CuOx-LDL. Therefore, only IgM to MDA-LDL, IgM to CuOx-LDL, and IgG to CuOx-LDL were additionally analyzed. No statistical correlation was observed between any subclass of antibodies and the traditional risk factors for atherosclerosis (age, gender, LDL cholesterol, systolic blood pressure, or smoking). Also, medications or concomitant diseases did not have a statistically significant influence on the antibody levels. Figure 1 shows the IMT of all the study subjects in various tertiles of IgM autoantibodies to MDA-LDL in the different parts of the carotid artery. The IMT was lowest in the highest antibody tertile in all parts of the vessel. This association remained significant after adjusting for the known risk factors of atherosclerosis (age, gender, LDL cholesterol, systolic blood pressure, CRP, and smoking) ( Figure 1 ), although the statistical significance was not reached in every section of the artery. In addition, the calculated mean IMT was lowest in the highest antibody titer, and this difference remained statistically significant after adjusting for covariates ( Figure 2 ). Similar results were seen in the measurements of maximal IMT and number of plaques, even though these were statistically significant only before adjusting for covariates ( Figure 2 ). Values are mean (SD) unless otherwise indicated. Table 2 presents data of autoantibody titers to another model of oxidized LDL, CuOx-LDL. Again, the IgM autoantibody titers to CuOx-LDL and also the IgG type of autoantibodies to CuOx-LDL seemed to be negatively associated with IMT. Before adjusting for the known risk factors of atherosclerosis, the IMT was lowest in the highest tertiles of antibodies in all parts of the carotid artery. Data for the mean IMT, maximal IMT, and the number of plaques are shown in Table 2 . After adjusting for other previously known risk factors, the significant differences, however, disappeared.
Finally, we measured the CRP values of the subjects. Previous studies have suggested that increased CRP values are related to increased atherosclerosis. 21 Before the adjustment there was a positive correlation between CRP and IMT ( Table 3 ). This correlation was seen in all segments of the vessel (data not shown), but after adjusting for the previously known risk factors, the correlation vanished in all parts of the carotid artery. Also, the linear trend toward greater number of plaques in higher tertiles of CRP disappeared after the adjustment. One previous study 22 has reported a positive correlation between CPR and IgG antibodies to OxLDL. In our study, however, we found no correlation between CRP and antibody levels.
Discussion
The major finding of this study was that circulating IgM type of autoantibodies to OxLDL is inversely related to subclinical atherosclerosis determined by the IMT of the carotid artery. In addition, these antibodies remained an independent negative risk factor for increased IMT after adjusting for other major known risk factors, such as age, gender, LDL cholesterol, systolic blood pressure, CRP, and smoking.
Lipoprotein oxidation is one of the early events in atherosclerotic process. Polyunsaturated fatty acids in LDL particles undergo lipid peroxidation, forming hundreds of different kinds of oxidation products, many of which are highly reactive and additionally modify closely associated proteins and lipids. 23 These newly formed modified structures are no longer recognized as "self" structures, and, therefore, an immune response rises against them. In animal models of atherosclerosis, such as apolipoprotein E-deficient mice, autoantibodies to OxLDL have been shown to strongly correlate to measures of atherosclerosis. 7 Autoantibodies to OxLDL have also been intensively studied in human populations, both in patients with cardiovascular disease as well as in healthy populations. One of the very earliest studies reported that the baseline titer of IgG autoantibodies to MDA-LDL predicted progression of carotid IMT in a group of 30 healthy Finnish men. 12 Since this initial report, many studies have shown a relationship between autoantibody titers to OxLDL and various cardiovascular diseases or risk factors, such as coronary artery disease, myocardial infarction, peripheral vascular disease, hypertension, preeclampsia, or diabetes. 24 So far, in most of the studies, the relationship between the autoantibodies to OxLDL and measures of atherosclerosis have been positive, suggesting that these antibodies could be markers of the progression of the disease or that they may even play an active role and enhance the progression of the disease. However, the results from our present study clearly demonstrate that those subjects having the highest titers of IgM type of autoantibodies binding to a classical model of OxLDL, MDA-LDL, have the lowest IMT in their carotid arteries. In the present study, we have not examined the possible underlying mechanisms for this finding. It is possible that instead of having an active role in the atherosclerotic diseases, these antibodies are merely markers. Thus, lower level of antibodies in the individuals with more extensive disease may be attributable to, for example, con-sumption of antibodies into the plaques. However, on the basis of the earlier studies, we may speculate that these types of antibodies may play a protective role in atherosclerosis.
There are several lines of earlier data supporting our hypothesis that there also exists a protective type of antibodies to OxLDL in vivo, and these data also provide important mechanistic insights. Several years ago, when working together with Professor Witztum's group, we cloned natural IgM type of monoclonal autoantibodies from apolipoprotein E-deficient mice having extremely high titers of autoanti- bodies to a wide variety of oxidation-specific epitopes without any exogenous immunization. 18 Of great interest was that most of these OxLDL-specific monoclonal autoantibodies had important biological properties, such as being able to block the binding and degradation of OxLDL by macrophages. 17 Since uptake of OxLDL by macrophages and formation of foam cells is one of the key events in atherosclerosis, it suggested that these antibodies could play a protective role in vivo in atherosclerosis. In addition, because such oxidized epitopes exist on circulating LDL in vivo, these antibodies could enhance the removal of oxidatively modified lipoproteins from plasma and prevent their entrance into the arterial wall. 25 In the present study, both IgM (to CuOx-LDL and MDA-LDL) and IgG (to CuOx-LDL) types of antibodies were negatively associated with IMT before adjusting for confounding factors. However, it is interesting that after the adjustments, only IgM type of antibodies was inversely related to carotid atherosclerosis. We can speculate that IgG type of antibodies does not have similar blocking properties as discussed above for IgM. Instead, IgG molecules have Fc-domain, which may even enhance the uptake of OxLDL through the Fc-receptors on macrophages. The other line of data suggesting that there exists a protective type of antibodies in vivo is the immunization studies with OxLDL. Palinski et al 8 first reported that immunization of WHHL rabbits with MDA-LDL inhibits the progression of atherogenesis, and this finding has been confirmed with several other animal models. 9 -11,26 Of special importance, a recent study by Zhou et al 11 demonstrated not only that immunization with MDA-LDL protected against atherosclerosis but also that the increased titers of antibodies were negatively related to the degree of lesion formation. Immunization with MDA-LDL results in a strong increase of antibodies, not only to MDA-LDL but also to a variety of other oxidative neoepitopes that may be present on OxLDL, such as oxidized phospholipids, oxidized cholesterol, oxidized cholesteryl linoleate, and oxidized cardiolipin. 10, 11 Again, it can be hypothesized that high titers of antibodies to the oxidation-specific epitopes enhance formation of immune complexes with minimally modified LDL, which leads to its rapid removal from the circulation before it enters the vascular wall.
Although the general deem so far has been that high antibody titers to OxLDL are related to increased atherosclerosis, in addition to our present study, there have been few other studies suggesting the opposite. 13, 27 In addition, a study by Wu et al 28 recently showed that autoantibodies to oxidized LDL were lower in men with borderline hypertension compared with age-matched controls. One explanation for the inconsistencies between the different studies may be because of the preparation of the antigens. The in vitro preparation of OxLDL will vary from one preparation to another within one laboratory and between different laboratories, and one main reason for this is that the isolated LDL preparations are never identical (eg, the antioxidant content). Therefore, each Ox-LDL preparation should be routinely tested for the degree of oxidation. However, the conditions for antigen preparation and controlling are seldom published and therefore difficult to compare. Another explanation for the inconsistencies between the different studies may be the different study populations. Atherosclerosis is a chronic inflammatory process that involves complex interplay of circulating cellular and blood elements. 2, 3 High amount of OxLDL in circulation does not necessarily lead to high antibody titers to OxLDL. In fact, it has been shown that the amount of circulating OxLDL is inversely related to the antibody titers to OxLDL. 29 The role of the humoral immune response may vary between different patient groups as well as at different stages of the disease. In addition, certain isotypes of antibodies may possess protective properties, whereas others may be harmful. Our study sample is so far the largest population published (nϭ1022) where antibodies to OxLDL and the IMT have been measured. In addition, it should be emphasized that the study subjects were not selected high-risk individuals but subjects from a random population-based cohort that is a representative sample of the Finnish middle-aged population.
In this study, we found no independent role of CRP in determining IMT. CRP is strongly associated with the traditional risk factors of atherosclerosis and especially those of the metabolic syndrome. 30 It may therefore be a marker of increased risk for atherosclerotic diseases rather than a cause of them. Lack of association between CRP and subclinical atherosclerosis has been previously reported, assessed both with IMT 31 and electron beam computed tomography. 32 It has thus been suggested that CRP may predict the risk of cardiovascular diseases by indicating inflammation that leads to the atherothrombotic events or by directly interacting with the atherosclerotic vessels promoting inflammation and thrombosis. 21 Our results may also support the findings of Hashimoto et al, 33 who have shown that CRP concentration is a marker of atherosclerotic activity rather than the extent of atherosclerosis.
In conclusion, experimental animal models of atherosclerosis have clearly shown that vaccination with OxLDL ameliorates atherosclerosis. We have shown that increased antibody titers to OxLDL have an independent inverse association with subclinical atherosclerosis in humans. Our present data support the recent view that induction of humoral immune response to oxidized neoepitopes may be beneficial, 34 and prospective studies are urgently needed to additionally assess whether these antibodies are protective in atherosclerosis in humans.
